Download Breast Cancer

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Prostate-specific antigen wikipedia, lookup

Transcript
Innovative GaN HEMT based Biosensor
Group 4
Instructor:
• National Chiao Tung University
Compound Semiconductor Device Laboratory
Professor Edward Yi Chang
• National Tsing Hua University
Professor Chuan-Kai Lee
GROUP 4
CVO
Eileen
CTO
Simon
CEO
Celine
CFO
Annie
CPO
Zoey
Outline
• What is our aim target on GaN based
biosensor
• First disease: Diabetes
• Second disease: Breast cancer
• Third disease: Prostate cancer
• New way: Can’tDia
• Suggestions
Why we want to aim on Biosensor
The market is growing!
The Advantages of GaN HEMT
Based Biosensor
1
2
3
Low noise due to high eletron mobility
Very sensitive to surface charges’ change
Good stability to chemical
Therefore, we can use GaN based Biosensor to
replace the original Silicon Based Biosensor
Summary of surface functional layers used with
GaN HEMT-based sensor
Detection
Mechanism
Surface Functionalization
H2
Catalytic
Pd, Pt
Pressure change
Polarization
Polyvinylidence difluoride
Botulinum toxin
antibody
Thioglycolic acid/ antibody
Proteins
Conjugation/ hybridization
Aminopropylsilane/ biotin
PH
Adsorption of polar molecules
Sc2O3, ZnO
Hg2+
chelation
Thioglycolic acid/ Au
KIM-1
antibody
KIM-1 antibody
Glucose
GOX immobilization
ZnO nanorods
Prostate Specific Antigen
PSA antibody
Carboxylate succimdyl ester/ PSA
antibody
Lactic acid
LOX immobilization
ZnO nanorods
Chloride ions
Anodization
Ag/ AgCl electrodes; InN
Breast Cancer
antibody
Thyioglycolic acid/c-erbB antibody
CO2
Absorption of water/ charge
Polyethylenimine/ starch
DNA
hybridization
3’-thiol-modified oligonucleotides
O2
oxidation
InGaZnO
Summary of surface functional layers used with
GaN HEMT-based sensor
Detection
Mechanism
Surface Functionalization
H2
Catalytic
Pd, Pt
Pressure change
Polarization
Polyvinylidence difluoride
Botulinum toxin
antibody
Thioglycolic acid/ antibody
Proteins
Conjugation/ hybridization
Aminopropylsilane/ biotin
PH
Adsorption of polar molecules
Sc2O3, ZnO
Hg2+
chelation
Thioglycolic acid/ Au
KIM-1
antibody
KIM-1 antibody
Glucose
GOX immobilization
ZnO nanorods
Prostate Specific Antigen
PSA antibody
Carboxylate succimdyl ester/ PSA
antibody
Lactic acid
LOX immobilization
ZnO nanorods
Chloride ions
Anodization
Ag/ AgCl electrodes; InN
Breast Cancer
antibody
Thyioglycolic acid/c-erbB antibody
CO2
Medical
part
Absorption of water/ charge
DNA
hybridization
3’-thiol-modified oligonucleotides
O2
oxidation
InGaZnO
Polyethylenimine/ starch
1st
Applications of biosensor
based on GaN in medical
field
Cancer is leading
cause of death
Applications of biosensor
based on GaN in medical
field
We should develop the
GaN based biosensor in
the usage of diabetes,
breast cancer and
prostate cancer
Diabetes
------------------------------------------------
Number of people with diabetes
In Taiwan
2,000,000
1,500,000
1,000,000
500,000
2002 2003
2004 2005
2006
Total
Male
Female
2007
2008
2009
Glucose as diabetes biomarker
Quantitation of the glucose
content
is
of
extreme
importance, as it is the main
diabetes
biomarker.
Optimal
management
of
diabetes involves patients
measuring and recording
their own blood glucose
levels.
Blood Glucose Monitoring
Traditional Home Blood
Glucose Monitoring
The traditional method of testing
blood glucose involves:
• pricking finger with a lancet
• putting a drop of blood on a test
strip
• placing the strip into a meter that
displays blood glucose level.
Imperfection
• uncomfortable for the user
• complex procedures
Meters That Test
Alternative Sites
Newer meters allow test sites
other than fingertip, include:
• upper arm
• forearm
• base of the thumb
• thigh
Imperfection
• Results are different from the
blood glucose levels obtained
from the fingertip .
• The results are not reliable.
Continuous Glucose
Monitoring System
Some of these devices are
combined with insulin pumps. They
can be used to see patterns and
trends.
Imperfection
• is not as accurate as finger
stick glucose results
• expensive in terms of costs
3~4
times/day
However, frequent self-monitoring
of
glucose
concentrations
is
difficult, given:
• the time
• the inconvenience
• the discomfort
• the complex procedures
• the expensive cost
involved with the traditional
measurement technique.
The
American
Diabetes
Association recommends that:
• insulin-dependent type 1
diabetics
selfmonitor
blood glucose 3–4 times
daily
• insulin-dependent type 2
diabetics monitor oncedaily
So
Difficult!
It is necessary to develop such
a approach:
NONINVASIVE
ACCURATE
SENSITIVE
S!MPLE
MICROVOLUME
LOW-COST
Non-invasive glucose sensing is the ultimate goal of
glucose monitoring
The main approaches being pursued for glucose sensor
development are:
• Near infrared spectroscopy
• Excreted physiological fluid (tears, sweat, urine, saliva)
analysis
• Microcalorimetry, enzyme
• Electrodes
• Optical sensors
• Sonophoresis and iontophoresis, both of which extract
glucose from the skin
Glucose biosensors
A
D
V
A
N
T
A
G
E
Relative easy of use
Speed
Minimal risk of infection involved with infrared spectroscopy
Low sensitivity
Poor selectivity
Frequently required calibrations
Difficulties with miniaturization
D
I
S
A
D
V
A
N
T
A
G
E
GaN High Electron Mobility
Transistor Based Biosensors
Breast
Cancer
-----------------------------------------------
Estimated New Cancer Cases and Deaths Worldwide for
Leading Cancer Sites by Level of Economic Development,
2008
Estimated New Cases
Worldwide
Estimated Deaths
Incidence of Cancer In Taiwan
Death Rate
Early Detection
Breast cancer screening for women at average risk includes
clinical breast exam and mammography. Mammography can
often detect breast cancer at an early stage, when treatment is
more effective and a cure is more likely. Numerous studies have
shown that early detection with mammography saves lives and
increases treatment options.
- American Cancer Society
Breast Cancer Examination
Breast
Self-examination
20+
Monthly
• Not sensitive
• Low performance rate
Clinical Breast
Examination
20s-30s
Every Three Years
•
Hospital only
Mammography &
Breast Ultrasound &
Magnetic Resonance
Imaging
40+
Annually
• Radiation exposure and
uncomfortable process
• Rely on doctor experience,
supporting Mammography
• Injection contrast medium
and costly
Breast cancer marker: c-erbB-2 antigen
Normal patient
4-6 µg/ml
Breast Cancer Patient
9-13 µg/ml
•
•
•
•
Patient
Saliva
The limit of detection of
this device was 0.25
μg/ml c-erbB-2 antigen
in PBS buffer solution.
Sensitive
Portability
Non-Invasive
Easy to use
Prostate
Cancer
-----------------------------------------------
Estimated New Cancer Cases and Deaths Worldwide for
Leading Cancer Sites by Level of Economic Development,
2008
Estimated New Cases
Worldwide
Estimated Deaths
Incidence of Cancer
Death Rate
Prostate Cancer Examination
Prostate cancer
antigen blood test
Digital rectal exam
(DRE)
50+
Every Year
•
Hospital only
•
•
•
Costly
Time-consuming
Need sample
transportation
Prostate cancer marker: Prostate-specific antigen (PSA)
Normal patient
<4 ng/ml
Blood
25% chance
4-10 ng/ml
50% chance
>10 ng/ml
The range of detection of
this device was 1 μg/ml 10 pg/ml PSA
Can’t Dia
The Linkage between Diabetes and Cancers
• Type 2 diabetes is associated with increased risk for some
cancers.
(liver, pancreas, endometrium, colon and rectum, breast,
bladder).
• Only for prostate cancer is diabetes associated with a lower
risk.
---Adopted from Diabetes and Cancer (a consensus report)
Find a New Way!!!
Diabetes
+
Breast Cancer
=
A Biosensor can
both diabetes
breast cancer
detect
and
Conclusion and Suggestion
Possible Collaborator
Target Customer
Diabetes
五鼎生物技術股份有限公司
台欣科技研發股份有限公司
華廣生技股份有限公司
Diabetic
Prostate Cancer
亞諾法生技股份有限公司
台灣基康股份有限公司
Hospital and Clinics
Breast Cancer
超微基因偵測科技股份有限公司 Hospital and Clinics
台灣基康股份有限公司
麥利亞德基因科技公司
Diabetes+ Breast
Cancer
超微基因偵測科技股份有限公司 40+ years old women
台灣基康股份有限公司
who get diabetes
麥利亞德基因科技公司
Suggestion
• Biosensor is a potential market, especially in diagnosis
application, according to our study, the potential is
diabetes > breast cancer > prostate cancer.
• Can’t Dia is from the concept of combination drug,
through the same testing procedure but monitoring
patient’s cancer risk at the same time, having niche to
enter the market.
Thank You